PRKAR2B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL29637723	0.94	7/20
SCHEMBL24473663	0.52	6/20
SCHEMBL25758456	0.46	6/20
SCHEMBL24473534	0.46	6/20
SCHEMBL24473539	0.53	5/20
SCHEMBL24473602	0.52	5/20
SCHEMBL17568826	0.52	5/20
SCHEMBL18053128	0.52	5/20
SCHEMBL24473339	0.51	5/20
SCHEMBL24473505	0.51	5/20
SCHEMBL24473579	0.46	5/20
SCHEMBL24473637	0.46	5/20
SCHEMBL24473416	0.46	5/20
SCHEMBL26181835	0.36	5/20
SCHEMBL17880428	0.49	2/20
SCHEMBL18053760	0.48	2/20
SCHEMBL24473338	0.45	2/20
SCHEMBL18824835	0.30	2/20
SCHEMBL21218596	0.30	2/20
SCHEMBL21218597	0.30	2/20

Clinical trials — most relevant to PRKAR2B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate	PHASE2/PHASE3	WITHDRAWN
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	COMPLETED
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	ACTIVE_NOT_RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals	PHASE1/PHASE2	COMPLETED
Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle	PHASE2	NOT_YET_RECRUITING
PKC412 and 5-Azacytidine	PHASE1/PHASE2	COMPLETED
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes	PHASE2	RECRUITING
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients	PHASE2	COMPLETED
Metformin for Fibromyalgia Symptoms (INFORM Trial)	PHASE2	RECRUITING
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.	PHASE1	COMPLETED
Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases.	nan	NOT_YET_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Effect of Age on Glucose and Lipid Metabolism	nan	COMPLETED
Free Fatty Acid Induced Insulin Resistance	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
cAMP Signaling and Muscle Adaptations	nan	UNKNOWN
Ischemic Preconditioning to Prevent Acute Kidney Injury	nan	COMPLETED
Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis	nan	NOT_YET_RECRUITING
Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH	nan	COMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PRKAR2B binder may also engage these)

Protein	Name	Similarity
P31322	—	1.000	P31322 →
P12369	—	1.000	P12369 →
P31324	—	1.000	P31324 →
P12368	—	0.998	P12368 →
P00515	—	0.994	P00515 →
P12367	—	0.992	P12367 →
PRKAR2A	cAMP-dependent protein kinase type II-alpha regulatory subunit	0.985	landscape →
O14448	—	0.966	O14448 →
Q9C1C2	—	0.965	Q9C1C2 →
Q01386	—	0.959	Q01386 →
P16905	—	0.956	P16905 →
P31319	—	0.950	P31319 →
O88506	—	0.947	O88506 →
Q9C196	—	0.946	Q9C196 →
Q9HEP7	—	0.944	Q9HEP7 →
Q863I2	—	0.944	Q863I2 →
O59922	—	0.943	O59922 →
Q96UX3	—	0.939	Q96UX3 →
P30625	—	0.939	P30625 →
OXSR1	Serine/threonine-protein kinase OSR1	0.938	landscape →
Q86ZN7	—	0.938	Q86ZN7 →
A0A8I5ZNK2	—	0.936	A0A8I5ZNK2 →
Q62696	—	0.936	Q62696 →
Q9Z1W9	—	0.935	Q9Z1W9 →
Q6P9R2	—	0.934	Q6P9R2 →
STK39	STE20/SPS1-related proline-alanine-rich protein kinase	0.933	landscape →
Q9SIZ2	—	0.932	Q9SIZ2 →
PRKD1	Serine/threonine-protein kinase D1	0.932	landscape →
Q93VD3	—	0.932	Q93VD3 →
Q5R495	—	0.932	Q5R495 →